RAD51 and prostate carcinoma: However, other findings have not supported these results, showing no impact on RAD51 expression and foci formation by PTEN deficiency, and only mild sensitivity of PTEN-deficient cells to PARP inhibition in primary prostate cancer cell lines and xenografts [37].